4 results
Approved WMOCompleted
The key objective of this study is to assess next-day residual effects of MK-4305 (20 and 40 mg) via driving performance after 1 day of dosing and after 8 days of dosing.
Approved WMOWill not start
The purpose of this study is to evaluate the possible risks and efficacy (improvement of disease) with an experimental oral study drug named eliglustat in pediatric patients from 2 to 18 years with Gaucher disease.
Approved WMOWill not start
Evaluate the performance and safety of HASS 200 (HARMONY AORTIC STIMULATION SYSTEM) in treatment of heart failure subjects.
Approved WMOCompleted
Evaluate the performance and safety of HASS 200 (HARMONY AORTIC STIMULATION SYSTEM) in treatment of heart failure subjects.